MarketCap
Facebook
X
Telegram
Precipio Market Cap | PRPO
As of September 04, 2026 Precipio has a market cap of $ 41.9 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Precipio
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 38.4 M | 35 M | 8.7 M | 774 K | 32.3 M | 45.5 M | 11 M | 4.22 M | 5.34 M | 16.1 M | 7.89 M | 28 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 45.5 M | 774 K | 19.4 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Diagnostics research industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
57.5 K | - | -8.98 % | $ 14.8 K |  USA |
 |
QIAGEN N.V.
QGEN
|
8.52 B | - | - | $ 10.6 B |  Niderland |
 |
Centogene N.V.
CNTG
|
10.7 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
DarioHealth Corp.
DRIO
|
32.8 M | $ 6.98 | 1.51 % | $ 27.8 M |  Israel |
 |
Charles River Laboratories International
CRL
|
7.69 B | $ 293.35 | 0.54 % | $ 14.5 B | USA |
 |
Aspira Women's Health
AWH
|
3.03 M | - | -6.19 % | $ 10.5 M | USA |
 |
ICON Public Limited Company
ICLR
|
10.1 B | $ 163.58 | 2.34 % | $ 12.8 B |  Irlanda |
 |
Brainsway Ltd.
BWAY
|
301 M | $ 14.51 | 1.61 % | $ 493 M | Israel |
 |
Celcuity
CELC
|
5.37 B | $ 96.43 | 0.24 % | $ 4.51 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
421 M | - | - | $ 562 M |  Britain |
 |
Check-Cap Ltd.
CHEK
|
4.33 M | - | - | $ 9.42 M | Israel |
|
Akumin
AKU
|
75.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
4.03 M | - | -61.36 % | $ 2.46 M | USA |
 |
Mettler-Toledo International
MTD
|
28.4 B | $ 1 356.23 | 0.66 % | $ 28 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
409 M | $ 3.23 | 1.57 % | $ 299 M | USA |
 |
Biocept
BIOC
|
5.93 M | - | -13.05 % | $ 7.29 M | USA |
 |
Global Cord Blood Corporation
CO
|
304 M | - | - | $ 399 M |  China |
 |
ENDRA Life Sciences
NDRA
|
3.66 M | $ 5.68 | 22.58 % | $ 4.47 M | USA |
 |
Fluidigm Corporation
FLDM
|
481 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
133 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
404 M | - | 0.12 % | $ 80.1 M | China |
 |
Chembio Diagnostics
CEMI
|
12.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
National Research Corporation
NRC
|
315 M | $ 21.25 | 6.2 % | $ 476 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
7.87 B | - | - | $ 10.7 B | USA |
 |
OPKO Health
OPK
|
1.04 B | $ 1.61 | 11.18 % | $ 1.21 B | USA |
 |
DermTech
DMTK
|
42.4 M | - | -11.32 % | $ 2.94 M | USA |
 |
Pacific Biosciences of California
PACB
|
498 M | $ 1.3 | 3.13 % | $ 390 M | USA |
 |
Personalis
PSNL
|
431 M | $ 16.83 | 0.6 % | $ 1.5 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
23.3 B | $ 239.4 | 2.07 % | $ 26.6 B | USA |
 |
DexCom
DXCM
|
25.5 B | $ 89.71 | 0.02 % | $ 35 B | USA |
 |
Heska Corporation
HSKA
|
844 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
2.99 M | - | -20.0 % | $ 1.06 M | USA |
 |
Soleno Therapeutics
SLNO
|
2.08 B | - | - | $ 2.69 B | USA |
 |
Psychemedics Corporation
PMD
|
16.8 M | - | -1.84 % | $ 15.3 M | USA |
 |
Motus GI Holdings
MOTS
|
990 K | - | -34.28 % | $ 263 K | Israel |
 |
Syneos Health
SYNH
|
9.41 B | - | - | $ 4.46 B | USA |
 |
Invitae Corporation
NVTA
|
511 M | - | - | $ 21.2 M | USA |
 |
Organovo Holdings
ONVO
|
3.1 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
9.12 M | - | -16.95 % | $ 1.54 M | USA |
 |
T2 Biosystems
TTOO
|
7.78 M | - | -39.35 % | $ 313 K | USA |
 |
Anixa Biosciences
ANIX
|
104 K | $ 3.05 | 0.64 % | $ 99 K | USA |
 |
Neuronetics
STIM
|
81.1 M | $ 2.72 | 0.18 % | $ 179 M | USA |
 |
PerkinElmer
PKI
|
14.1 B | - | -0.91 % | $ 14.7 B | USA |
 |
Meridian Bioscience
VIVO
|
1.38 B | - | - | $ 1.49 B | USA |
 |
Quotient Limited
QTNT
|
237 M | - | -11.32 % | $ 1.1 M | Schweiz |
 |
Renalytix AI plc
RNLX
|
22.7 M | - | 5.66 % | $ 22.7 M | Britain |
 |
Interpace Biosciences
IDXG
|
7.34 M | $ 1.45 | 2.11 % | $ 6.41 M | USA |
 |
IQVIA Holdings
IQV
|
28.3 B | $ 271.62 | 2.95 % | $ 46.7 B | USA |
 |
Surmodics
SRDX
|
554 M | - | - | $ 608 M | USA |
 |
Quidel Corporation
QDEL
|
10.6 B | $ 13.93 | 1.45 % | $ 587 M | USA |